- Presenter: Kenneth Flanagan, Prothena Biosciences Inc
- Session: 3802/ Research Advancement in Allergy and Inflammation
- Date and Time: Sunday, March 6, 2016, 4:45 p.m. - 6:15 p.m. PST
- Location: Los Angeles Convention Center, Level One, Concourse, Foyer
Forward-looking StatementsThis press release contains forward-looking statements. These statements relate to, among other things, PRX003's method of action and whether it will be useful for treating a variety of inflammatory diseases. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to the risks, uncertainties and other factors described in the "Risk Factors" sections of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2016 and our subsequent Quarterly Reports on Form 10-Q filed with the SEC. Prothena undertakes no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events or changes in Prothena's expectations.
Contacts:Investors: Tran Nguyen, CFO650-837-8535, IR@prothena.comMedia: Ellen Rose, Head of Communications 650-922-2405, email@example.com